This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Health product recall

BD BBL Sensi Disc Ampicillin 2 Μg (AM-2)

Last updated

Summary

Product
BD BBL Sensi Disc Ampicillin 2 Μg (AM-2)
Issue
Medical devices - Performance
What to do

Contact the manufacturer if you require additional information. 

Audience
Industry

Affected products

Affected products Lot or serial number Model or catalog number
BD BBL Sensi Disc Ampicillin 2 Μg (AM-2) 3234190 3184064 2339360 3010977 231263

Issue

BD identified through potency test, as part of special stability test requests to monitor Ampicillin AM-2, unsatisfactory results of 65% at 18 months. The potency acceptance criteria is 80-140% and product shelf life is 24 months. A retest with control batch and extended sampling confirmed the low potency results.

Recall Start Date: November 6, 2024

Additional information

Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Medical devices - Microbiology
Companies

Becton Dickinson And Company (Bd)

7 Loveton Circle, Sparks, Maryland, United States, 21152

Published by
Health Canada
Audience
Industry
Recall class
Type II
Identification number
RA-76548

Get notified

Receive emails about new and updated recall and safety alerts.

Subscribe